Skip to main
SBRA

SBRA Stock Forecast & Price Target

SBRA Analyst Ratings

Based on 9 analyst ratings
Hold
Strong Buy 11%
Buy 22%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Sabra Health Care REIT is set for growth in the long term, supported by strong senior housing occupancy rates, an attractive acquisition pipeline with a diversified portfolio, and successful rent re-tenanting initiatives. The company's recent debt repayment and expected completion of transitioning all Avamere properties will also contribute to a stronger balance sheet and create incremental cash flow. Strong demographics and limited new supply in the healthcare market also provide a positive outlook for Sabra Health Care REIT's performance.

Bears say

Sabra Health Care REIT is a healthcare real estate investment trust that operates in a highly competitive industry, making it challenging for the company to acquire attractive assets. Additionally, SBRA's reliance on external sources of capital and a high debt level could limit its ability to fund future investments and meet obligations. The company also faces risks from potential non-compliance by its operators with healthcare regulations and reimbursement cuts from government and third-party payers. With a limited competitive advantage and high leverage, SBRA's stock may continue to face pressure, as evidenced by its declining earnings estimates.

SBRA has been analyzed by 9 analysts, with a consensus rating of Hold. 11% of analysts recommend a Strong Buy, 22% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sabra Health Care and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sabra Health Care (SBRA) Forecast

Analysts have given SBRA a Hold based on their latest research and market trends.

According to 9 analysts, SBRA has a Hold consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.89, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.89, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sabra Health Care (SBRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.